Quarterly report [Sections 13 or 15(d)]

Consolidated Balance Sheets (Unaudited)

v3.25.2
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 13,026 $ 24,125
Inventory 948  
Income taxes receivable 0 48
Prepaid expenses and other current assets 916 614
Total current assets 14,890 24,787
Intangible asset, net 19,059 19,746
Property and equipment, net 12 23
Restricted cash 34 34
Other assets 19 5
Total assets 34,014 44,595
Current liabilities:    
Accounts payable 1,189 251
Accrued expenses 3,951 2,651
Exchangeable notes 0 14,463
Royalty-linked notes 190  
Income taxes payable 6  
Other current liabilities 197 240
Total current liabilities 5,533 17,605
Pfizer promissory note 20,653 20,300
Royalty-linked notes 11,715 10,771
Total liabilities 37,901 48,676
Commitments and contingencies (Note 16)
Shareholders' deficit    
Undesignated preferred shares, $0.01 par value per share: 100,000,000 shares authorized at June 30, 2025 and December 31, 2024; no shares issued at June 30, 2025 and December 31, 2024
Ordinary shares, $0.01 par value per share: 80,000,000 shares authorized at June 30, 2025 and December 31, 2024, 42,131,328 shares issued at June 30, 2025; 31,534,233 shares issued at December 31, 2024 421 315
Additional Paid in Capital 493,164 481,676
Accumulated deficit (497,472) (486,072)
Accumulated other comprehensive income 0 0
Total shareholders' deficit (3,887) (4,081)
Total liabilities and shareholders' deficit $ 34,014 $ 44,595